Is NanoString Technologies still an independent company?

No. NanoString filed Chapter 11 bankruptcy on February 4, 2024, and Bruker Corporation completed an asset acquisition on May 6, 2024 for about $392.6 million cash plus assumed liabilities. NanoString now operates as Bruker Spatial Biology, a division of Bruker, not a standalone public company.

Who owns NanoString now?

Bruker Corporation (Nasdaq: BRKR) owns NanoString's former assets after completing a $392.6 million asset purchase on May 6, 2024, following NanoString's Chapter 11 filing. The business runs as Bruker Spatial Biology alongside Canopy Biosciences and Bruker Spatial Genomics.

Who is NanoString's biggest competitor?

10x Genomics. It won a $31 million patent jury verdict against NanoString in November 2023, a factor in NanoString's February 2024 bankruptcy, and in May 2025 settled with new owner Bruker for $68 million in installments plus ongoing royalties on spatial-biology sales.

Did NanoString have layoffs before its bankruptcy?

Yes. NanoString cut 20% of its workforce in October 2023, months before withdrawing FY2023 guidance, seeing its stock drop more than 50% in a single day, and filing Chapter 11 bankruptcy on February 4, 2024.

Could AI replace NanoString's spatial biology products?

AI is being added to the downstream AtoMx informatics layer (AI cell segmentation models shown April 2025, an LLM-based Spatial Discovery query tool shown April 2026), but the underlying instruments, reagent chemistry, and imaging IP remain the moat AI software alone cannot replicate as of April 2026.

Is Bruker Spatial Biology (NanoString's successor) profitable?

Standalone financials are not disclosed; NanoString's business is folded into Bruker's BSI segment, which posted organic revenue down 5.1% year over year in Q4 2025 while Bruker overall reported $3.436 billion FY2025 revenue and called it a difficult year, per its February 11, 2026 results release.

Biotech tools companies · subsidiary of Bruker Corporation · United States

NanoString Technologies

nanostring.com ↗

Spatial genomics platform maker now folded into Bruker after 2024 bankruptcy.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from Q2 2026 · Every call on the record Checkpoint: Final installment of 10x Genomics $68M patent settlement due

The call

The NanoString name is gone, but its spatial genomics business lives on inside Bruker, still paying off the lawsuit that helped sink it.

NanoString sold gene-analysis tools for research, but filed for bankruptcy in early 2024 and was bought by larger company Bruker. The main problem is that competitor 10x Genomics won a patent lawsuit and is now collecting millions in payments through 2026, plus taking a cut of every sale Bruker makes in this area. The market itself is also getting smaller because research budgets are tighter. The one thing that could turn this around is if Bruker figures out how to grow sales again once the big settlement payments to 10x Genomics end in mid-2026, but there is no sign of that happening yet.

Why

AI pressure: None apparent. AI plays a role in image analysis for spatial data but no AI-native rival is displacing the platform itself. Could AI do the core job? Unlikely.

Bigger players: 10x Genomics. 10x won a $31M patent verdict, now collects $68M in settlement payments through Q2 2026 plus royalties on every spatial sale. Could a giant copy it? Probably.

What protects it. Installed base of GeoMx and CosMx instruments and Bruker's $3.4B balance sheet cover the legal bill and keep labs from switching gear.

What would change this call

Bruker Spatial Biology segment revenue trend in Q1/Q2 2026 filings. Whether the low-single-digit organic decline continues or reverses.
Whether the $68M 10x Genomics royalty settlement expires cleanly at Q2 2026. Shows if patent pressure from 10x Genomics eases or a new dispute emerges.
10x Genomics launches a next-generation spatial platform and its market share shift. Indicates whether 10x Genomics extends its lead over Bruker's spatial unit.

Key numbers

10x Genomics settlement: $68M through Q2 2026 plus royalties (2025-05-18)
Bruker FY2025 revenue $3.436B, Q4 flat year over year (2025-12-31)
NanoString 2023 assets $274.7M vs debts $325.3M before filing (2023-09-30)

Named risks

Ongoing $68M plus royalty payments to 10x Genomics through Q2 2026 drag on margins. Severity: high
Bruker BSI segment organic revenue declined 5.1% yoy in Q4 2025 amid academic funding cuts. Severity: high
Multi-acquisition integration risk combining NanoString, Canopy Biosciences, Bruker Spatial Genomics. Severity: medium
Recurring patent litigation exposure in spatial genomics category from 10x Genomics. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
10x Genomics	losing to	Won $31M verdict Nov 2023 that helped trigger NanoString bankruptcy; $68M settlement paid through Q2 2026
Vizgen	contesting	Competing MERSCOPE spatial platform; separate 10x patent suit against Vizgen dismissed Feb 2025
Illumina	contesting	Broader genomics incumbent that could expand into spatial biology, per background market context
Thermo Fisher Scientific	contesting	Dominant life-science tools incumbent adjacent to spatial genomics category

Questions people ask

Is NanoString Technologies still an independent company?: No. NanoString filed Chapter 11 bankruptcy on February 4, 2024, and Bruker Corporation completed an asset acquisition on May 6, 2024 for about $392.6 million cash plus assumed liabilities. NanoString now operates as Bruker Spatial Biology, a division of Bruker, not a standalone public company.
Who owns NanoString now?: Bruker Corporation (Nasdaq: BRKR) owns NanoString's former assets after completing a $392.6 million asset purchase on May 6, 2024, following NanoString's Chapter 11 filing. The business runs as Bruker Spatial Biology alongside Canopy Biosciences and Bruker Spatial Genomics.
Who is NanoString's biggest competitor?: 10x Genomics. It won a $31 million patent jury verdict against NanoString in November 2023, a factor in NanoString's February 2024 bankruptcy, and in May 2025 settled with new owner Bruker for $68 million in installments plus ongoing royalties on spatial-biology sales.
Did NanoString have layoffs before its bankruptcy?: Yes. NanoString cut 20% of its workforce in October 2023, months before withdrawing FY2023 guidance, seeing its stock drop more than 50% in a single day, and filing Chapter 11 bankruptcy on February 4, 2024.
Could AI replace NanoString's spatial biology products?: AI is being added to the downstream AtoMx informatics layer (AI cell segmentation models shown April 2025, an LLM-based Spatial Discovery query tool shown April 2026), but the underlying instruments, reagent chemistry, and imaging IP remain the moat AI software alone cannot replicate as of April 2026.
Is Bruker Spatial Biology (NanoString's successor) profitable?: Standalone financials are not disclosed; NanoString's business is folded into Bruker's BSI segment, which posted organic revenue down 5.1% year over year in Q4 2025 while Bruker overall reported $3.436 billion FY2025 revenue and called it a difficult year, per its February 11, 2026 results release.

Timeline

2026-04-16AACR 2026: Bruker Spatial Biology launches cross-platform GeoMx-to-CellScape workflows
2026-02-22AGBT 2026: CellScape XR spatial proteomics platform launched, Glasgow collaboration announced
2026-02-12Bruker reports FY2025 results, BSI segment organic revenue down 5.1% yoy
2025-05-18Bruker settles 10x Genomics patent suits for $68M installments plus royalties
2025-04-24AACR 2025: CosMx 2.0 and AI cell segmentation models launched on AtoMx
2025-02-20AGBT 2025: PaintScape, CosMx WTX, PowerOMX launched
2024-05-06Bruker completes $392.6M asset acquisition of NanoString
2024-04-17Bruker signs asset purchase agreement for NanoString business
2024-02-04NanoString files Chapter 11 bankruptcy in Delaware
2023-1110x Genomics wins $31M patent jury verdict against NanoString

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation